Breast cancer
Open
Phase 3
This trial is looking at a new drug called camizestrant for that has a medium to high risk of coming back. It is comparing camizestrant with .
It is for people whose breast cancer has:
many receptors for the hormone oestrogen () and
only a small number or no receptors for HER2. This is negative breast cancer.
You pronounce camizestrant as cami-zess-trant.
Recruitment start: 27 November 2023
Recruitment end: 31 March 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sacha Howell
AstraZeneca
Last reviewed: 12 Nov 2025
CRUK internal database number: 19929
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
